You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. LNTH INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- 2. An interpretable clinical-radiomics-deep learning model based on magnetic resonance imaging for predicting postoperative Gleason grading in prostate cancer: a dual-center study
- 3. Health Canada approves Celltrion's Stoboclo® and Osenvelt®(CT-P41), denosumab biosimilars for the treatment of all indications approved for the reference products, Prolia® and Xgeva®, respectively
- 4. Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
- 5. UTR Therapeutics Publishes Landmark Preclinical Data in Frontiers in Pharmacology Supporting IND Submission for First-in-Class c-MYC RNA Therapeutic
- 6. Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
- 7. A methodology for optimizing treatment head angle arrangement for multi-angle FLASH intensity modulated radiation therapy platforms
- 8. Clinical value of cystatin S in patients with colorectal cancer chemotherapy
- 9. Impact of glucose and lipid metabolic disorders on the risk of chronic post-operative pain syndrome after colorectal cancer surgery
- 10. Common over-the-counter medication slashes colorectal cancer recurrence in half
Last updated at 9:34 GMT
Hot News Makers
Health/Pharma Companies
-
37594.21
-
17966.12
-
8448.82
-
8438.31
-
7320.95
-
6603.59
-
5307.94
-
2728.84
-
2133.43
-
2070.89
Drugs, Treatments, Trials
-
14760.82
-
8692.08
-
8677.25
-
8565.99
-
4933.17
-
3619.05
-
3141.63
-
2943.72
-
2538.01
-
2463.49
Last updated at 9:10 GMT
